49
Participants
Start Date
April 12, 2021
Primary Completion Date
February 4, 2022
Study Completion Date
February 4, 2022
anti-CD14
4 mg/kg on Day 1, 2 mg/kg on Days 2-4 administered intravenously (IV)
Placebo
Placebo administered intravenously on Days 1-4
remdesivir
Remdesivir administered intravenously for 5 days beginning with a 200 mg loading dose on Day 1, followed by 100 mg/day on Days 2-5.
Sarasota Memorial Health Care System, Sarasota
Virginia Mason Medical Center, Seattle
Harborview Medical Center, Seattle
Swedish Medical Center, Seattle
University of Washington Medical Center-Montlake, Seattle
Collaborators (2)
University of Washington
OTHER
Implicit Bioscience
INDUSTRY
Vanderbilt University Medical Center
OTHER
PPD Development, LP
INDUSTRY
National Institute of Allergy and Infectious Diseases (NIAID)
NIH